Phase 2 trial of three schedules of CUE-101 administered before surgery or chemoradiotherapy in HLA-A*0201 positive patients with HPV16+ OPSCC.
Jesse M. Zaretsky(Washington University in St. Louis), Douglas Adkins(Washington University in St. Louis), Ryan S. Jackson(Washington University in St. Louis), Jason T. Rich(Washington University in St. Louis), Raymond J. Moniz, Sidharth V. Puram(Washington University in St. Louis), Sarah Pennock(Washington University in St. Louis), Jingxia Liu(Washington University in St. Louis), Jared Cohen(Brooke Army Medical Center), Matteo Levisetti, Patrik Pipkorn(Washington University in St. Louis), Riley Mullins(Washington University in St. Louis), Anish Suri(Bristol-Myers Squibb (United States)), Randal C. Paniello, Wade L. Thorstad(Washington University in St. Louis), Thomas F. Barrett(Washington University in St. Louis), Apollina Goel(University of Iowa), Steven N. Quayle(CTI BioPharma (Italy)), Jessica Ley(Washington University in St. Louis)
Cited by 2
Related Papers
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
|New England Journal of Medicine|2016|3.1k
Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer
|Cell|2017|2.6k
Genetic Mechanisms of Immune Evasion in Colorectal Cancer
|Cancer Discovery|2018|558